Osteoporosis affects almost 44 million men and women aged 50 and older in the United States, and evidence indicates that its prevalence is rising, particularly as life expectancy continues to increase (see the National Osteoporosis Foundation website). Similar statistics have been noted in Europe, Asia and Australia. Osteoporosis is manifested by fractures and enhanced skeletal fragility due to micro-architectural changes in the trabecular and cortical skeleton. Osteoporotic fractures cause significant morbidity and in many individuals lead to loss of productivity and a reduced quality of life. The mortality rate in the first year after a hip fracture is 20-30% and more than half of individuals who sustain a hip fracture are unable to return to their previous lifestyle There is a long latency period until the clinical onset of osteoporosis, and during this time there are profound alterations in bone remodelling, which is the basic homeostatic process that controls calcium balance and skeletal integrity 3 . Imbalances in the 'bone remodelling unit' , often due to accelerated bone turnover, are caused by increased bone resorption or reduced bone formation relative to resorption. The end result is a net loss of bone mass and qualitative changes in skeletal architecture, both of which greatly increase an individual's risk of fracture.
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. Primarily as a result of these fractures, health care costs from osteoporosis in the United States alone exceed 15 billion US dollars annually 2 .
There is a long latency period until the clinical onset of osteoporosis, and during this time there are profound alterations in bone remodelling, which is the basic homeostatic process that controls calcium balance and skeletal integrity 3 . Imbalances in the 'bone remodelling unit' , often due to accelerated bone turnover, are caused by increased bone resorption or reduced bone formation relative to resorption. The end result is a net loss of bone mass and qualitative changes in skeletal architecture, both of which greatly increase an individual's risk of fracture.
Until recently, treatment options for osteoporosis were limited to agents that prevented bone loss and partially reduced fracture risk by suppressing bone resorption, thereby recalibrating the remodelling unit to a new steady state in which bone turnover slowed down and bone mineral density (BMD) was maintained. Although the number of approved therapies for osteoporosis has more than doubled over the past 15 years, the level of fracture-risk reduction has not improved dramatically. Indeed, the currently available treatments for osteoporosis, assuming optimal compliance, only reduce the risk of non-vertebral fractures by 30-40% at best [3] [4] [5] [6] . Newer pharmacological agents that act on bone formation offer possibilities for building on earlier treatment successes. This has led some to speculate that these drugs can restore old skeletons to more youthful states. Such guarded optimism is due in part to a greater understanding of the molecular and cellular events that occur during acquisition of peak bone mass in adolescence and bone remodelling in adults. A new therapeutic paradigm in osteoporosis medicine is emerging from these findings -that is, a targeted molecular approach to enhance the inherent capacity of the skeleton to augment bone mass, regardless of age.
In this Review, we outline the physiology of the skeleton and discuss recent discoveries that provide new insights into bone remodelling and its relationship to energy and metabolic status. We briefly overview the
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evidence supporting current therapeutic approaches for osteoporosis, then focus on the pharmacological targeting of specific pathways that offer new possibilities for intervention, especially those that could stimulate bone formation. Finally, we discuss the potential commercial and regulatory challenges that must be overcome before final approval and marketing of these agents.
Overview of skeletal physiology
Trauma is the principal cause of fractures at any stage of life, but factors that alter the quality or quantity of bone mass further predispose a susceptible individual to fractures. The bone remodelling sequence is a critical determinant of both the amount and type of bone that is laid down across the lifespan. Remodelling is essential for preserving serum calcium and maintaining bone strength during adulthood. This cyclic process occurs within microscopic elements called remodelling or basic multicellular units (BMUs) 5 . Remodelling begins with bone dissolution or resorption and ends with bone formation; however, the precise sequence of initiation is still not fully understood.
Bone resorption is carried out by osteoclasts, which originate from the haematopoietic monocyte-macrophage lineage. New bone is formed by osteoblasts -cells of the fibroblast-stromal lineage that produce bone matrix proteins and synthesize a lattice for subsequent mineralization. Stromal cells are found in the marrow and are destined to become fat, bone or cartilage under the influence of differentiation factors within the marrow milieu. Osteocytes are osteoblasts that have successfully completed bone formation and are entombed within the bone matrix. Although these cells were originally considered inert, it is now apparent that they communicate with resting surface osteoblasts (bone lining cells) and, under the proper circumstances (for example, microcracks, gravitational forces or fluid shifts), they can initiate bone remodelling. Microcanaliculi connect osteoblasts to osteocytes and are likely to serve as the conduit for signals that originate from osteocytes in response to gravitational forces 5 .
Remodelling begins when osteocytes are activated by local factors (FIG. 1) or systemic modulators such as parathyroid hormone (PTH), interleukins, oestrogen withdrawal or hormones. Marrow stromal cells synthesize and release two cytokines, MCSF (macrophage colony-stimulating factor) and RANKl (receptor activator of NF-κB ligand), which enhance the recruitment and differentiation of osteoclasts. These cells cause bone resorption, and during this process they release growth factors such as transforming growth factor-β (TGFβ) from the matrix in order to recruit more osteoblasts 7 . This results in bone resorption followed by bone formation in a coupled remodelling sequence.
In adulthood, each remodelling unit is balancedresorption equals formation -and remodelling lasts between 90 and 130 days. Maintenance of bone density during remodelling ensures a readily available source of calcium for the body and a persistent reservoir of stored calcium. Before adult remodelling, acquisition of peak bone mass occurs, usually between 12 and 15 years of age. During this time, there is a tremendous increase in bone mass as a result of skeletal growth and modelling. Pubertal surges of gonadal steroids and growth hormone are considered critical for the increase in bone mass during adolescence.
longitudinal studies suggest that several factors regulate peak bone density, including dietary intake of specific nutrients, physical activity and, most importantly, genetic determinants. This view was established in both human and mouse models. However, despite intense efforts over the past decade to identify heritable determinants of bone mass, progress has been slow, partly because it has been recognized that polymorphic differences in many genes contribute to skeletal acquisition. These genes include those coding for vitamin D receptors, oestrogen receptors (ERs), PTH, collagen A1a and RANKl, among others.
Bone loss occurs after peak acquisition, when resorption exceeds formation. During the early menopause, oestrogen deficiency contributes to rapid skeletal loss. Additionally, with advanced age, bone formation is often compromised by multiple factors, including further loss of gonadal steroids, reduced vitamin D production and action, increased PTH secretion, and local generation of cytokines and growth factors that are inhibitory to osteoblasts. There has been less focus on the genetics of bone loss, although this is likely to be the major pathogenic process in the development of osteoporosis.
Current therapies for osteoporosis
Current therapies for osteoporosis target adult bone loss and are centred on restoring the balance between formation and resorption. Oestrogens, selective oestrogen receptor modulators (SERMs), bisphosphonates, calcitonin and denosumab (Prolia; Amgen) are all antiresorptives, although their sites of action may differ. Only one anabolic agent for osteoporosis treatment has been approved by US regulatory agencies: teriparatide (Forteo; Eli lilly and Co.), which is a recombinant form of human PTH. European agencies have also approved the use of PTH for postmenopausal osteoporosis. Below, we provide a brief overview of these therapies, and a summary is also provided in TABLeS 1,2.
Oestrogen. Oestrogen was extensively used for the prevention and treatment of osteoporosis before the development of bisphosphonates because it was effective in improving BMD. However, the most definitive data for the antifracture efficacy of oestrogen only came in 2002, and were published by the Women's Health Initiative (WHI) 8 . In that study, combined therapy (0.625 mg per day of conjugated equine oestrogen with 2.5 mg per day of medroxyprogesterone acetate) was associated with a significant reduction in hip fractures as well as all osteoporotic fractures 8 . Ironically, although the WHI was the most definitive trial on the antifracture efficacy of oestrogen therapy, this study also led to a marked reduction in the use of oestrogen for fracture-risk reduction owing to the increased risk of cardiovascular events and breast cancer 8, 9 . Given the risks associated with conventional doses of oestrogen (0.625 mg per day of conjugated equine oestrogens, which is equivalent to approximately 1.0 mg per day of oral micronized 17β-oestradiol or 0.05 mg per day of transdermal 17β-oestradiol), a number of 10, 11 . Importantly, for doses of 0.25 mg per day of 17β-oestradiol 6 , the adverse effect profile was similar in the oestrogen and placebo groups, with no statistically significant differences in breast tenderness, endometrial thickness or abnormal mammograms. Thus, low-dose oestrogen therapy, which keeps serum oestradiol levels well below the premenopausal range, is effective at improving BMD. However, it remains to be seen whether large-scale studies examining fracture and safety end points (for example, breast cancer and cardiovascular events) will ever be initiated using this approach, given the growing list of alternative agents to prevent and treat osteoporosis.
SERMs.
For a long time, there has been interest in identifying compounds with beneficial skeletal effects, but without the adverse breast, endometrial and cardiovascular effects associated with oestrogen treatment. SERMs are non-steroidal compounds with tissue-specific actions, possibly owing to the fact that these drugs induce a different conformation of the ER from oestradiol 12 . Raloxifene (Evista; Eli lilly and Co.) -at a dose of 60 mg per day -is the only SERM currently approved by the US Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis. It has been shown to reduce vertebral fracture risk by 30-50% relative to placebo in postmenopausal women with osteoporosis, but has not been shown to protect against non-vertebral or hip fractures 13 . Raloxifene also reduces the risk of developing breast cancer 14 and is neutral with regards to cardiovascular events; however, it does lead to an increased risk of venous thromboembolic disease, fatal stroke and hot flushes 15 . Several additional SERMs (idoxifene, levormeloxifene and arzoxifene) have been studied but their clinical development has been abandoned owing to either lack of efficacy for reducing non-vertebral fractures or increases in endometrial thickness. More recently, a large, randomized placebo-controlled trial with lasofoxifene (Fablyn; Pfizer) demonstrated that this drug significantly reduced the risk of both vertebral and nonvertebral fractures, ER-positive breast cancer, coronary heart disease and stroke 16 . However, lasofoxifene was also associated with an increased risk of venous thromboembolic events and hot flushes. In addition, one of the two doses tested (0.25 mg per day) resulted in a 37% increase in all-cause mortality; thus, the future status of this drug remains uncertain.
Another SERM, bazedoxifene (viviant; Pfizer), has been tested in a novel approach in combination with conjugated equine oestrogens. The rationale for this approach was that such a combination would improve BMD and reduce hot flushes, but without some of the other adverse effects (for example, on the endometrium and breast) that are associated with oestrogen therapy alone. In a study of 3,997 postmenopausal women, lindsay et al. 17 found that the combination of bazedoxifene and oestrogen increased BMD at multiple sites over 2 years, reduced the number of hot flushes and improved measures of vaginal atrophy, lipid parameters and homocysteine levels, with a similar incidence of breast pain and other adverse events compared to placebo 18 . However, in the 3-year fracture trial, new vertebral fractures were reduced with bazedoxifene, but non-vertebral fractures were not, relative to placebo 19 .
Bisphosphonates. Bisphosphonates are currently the most widely used drugs for the prevention and treatment of osteoporosis, owing to their potent effects in inhibiting bone resorption, ease of frequency of administration and lack of serious long-term non-skeletal effects. Structurally, they are chemically stable derivatives of inorganic pyrophosphate (PPI) and, like PPI, bisphosphonates have a very high affinity for bone mineral because they bind to hydroxyapatite crystals 20 . These drugs are potent inhibitors of bone resorption, and they do so by binding to and inhibiting the activity of farnesyl pyrophosphate synthetase, which is a key regulatory enzyme in the mevalonic acid pathway and is critical for the production of cholesterol, isoprenoid lipids and other sterols 21 . As a result, the isoprenylation of proteins (including the small guanosine triphosphatebinding proteins RAB, RAC and RHO, which regulate key osteoclast cellular activities such as stress fibre assembly, membrane ruffling and survival) is inhibited, resulting in varying degrees of apoptosis of osteoclasts 22 . There are currently four bisphosphonates approved in the United States for the prevention and/or treatment of osteoporosis: alendronate (Fosamax; Merck), risedronate (Actonel; Sanofi-Aventis), ibandronate (Bondenza; GlaxoSmithKline) and zoledronic acid (Zometa; Novartis) 20 . Alendronate, risedronate and ibandronate are administered orally (daily, weekly or monthly), but ibandronate can also be administered intravenously every 3 months and zoledronic acid (5 mg) is administered intravenously, either annually (for treatment) or every other year (for prevention).
All of these drugs are potent inhibitors of bone resorption and reduce the risk of vertebral fractures by 40-70% and hip fractures by 40-50%. Overall, nonvertebral fractures (that is, fractures that do not include the spine or hip) are suppressed by only 20-40% 20 with alendronate, risedronate or zoledronate. Ibandronate has not been shown to have non-vertebral fracture efficacy. With respect to cost, a yearly dose of zoledronic acid is much more expensive than generic alendronate, whereas risedronate and ibandronate are intermediate in price.
Although bisphosphonates are extremely useful agents for reducing fracture risk, concerns have been raised regarding their long-term safety. Osteonecrosis of the jaw, a painful condition with exposed bone in the oral cavity, has received perhaps the greatest attention 23 . The risk of this complication appears to be greatest in patients with cancer who receive high monthly doses of zoledronic acid or pamidronate, but this risk is in the range of 1 in 10,000 to 1 in 100,000 per patient treatment-years in patients receiving doses of bisphosphonates for the treatment of osteoporosis. More recently, a specific type of femoral fracture (subtrochanteric) has been associated with bisphosphonate use 24 . The risk of this complication remains uncertain 25 , and further studies are needed to define its true incidence as well as the pathogenesis of both osteonecrosis of the jaw and subtrochanteric femoral fractures. Notwithstanding the rare occurrence of these complications, significant concerns have been raised about long-term treatment with bisphosphonates. This in turn has led to a greater urgency for considering alternative approaches to osteoporosis therapy.
Denosumab. Osteoclast maturation is dependent on RANKl 26,27
, which is expressed on the surface of bone marrow stromal and/or osteoblast precursor cells, T cells and B cells 28 (FIG. 1) . RANKl binds its cognate receptor RANK on osteoclast lineage cells, and is neutralized by the soluble decoy receptor osteoprotegerin (OPG), which is also produced by osteoblastic lineage cells 29, 30 . Denosumab is a fully human monoclonal antibody that binds to RANKl, thereby reducing osteoclast differentiation, activity and survival, and leading to a decrease in bone resorption. Multiple trials using denosumab have been carried out in humans, the largest being the Phase III FREEDOM trial 31 , in which treatment with denosumab resulted in a 68% decrease in vertebral fractures, a 40% decrease in hip fractures and a 20% decrease in non-vertebral fractures, compared with placebo.
As oral bisphosphonates are currently the first-line therapy for osteoporosis, Brown et al. 32 compared the efficacy and safety of denosumab against oral alendronate in the DECIDE study. Postmenopausal women receiving denosumab treatment had significantly greater increases in BMD at all skeletal sites assessed (total hip, lumbar spine, femoral neck, trochanter and the distal one-third radius). Decreases in levels of bone turnover markers were also significantly greater in denosumab-versus alendronate-treated patients. Analysis by high-resolution peripheral quantitative computed tomography (HR-PQCT) demonstrated that although alendronate only reduced bone loss, denosumab partially restored cortical bone density 33 . These findings suggest that denosumab may reduce cortical porosity by allowing partial or complete filling of cortical pores.
A subsequent study, the STAND trial, included postmenopausal women who were previously treated with alendronate and switched to denosumab 34 . In subjects transitioning to denosumab, total hip BMD increased by 1.90% compared to a 1.05% increase in subjects continuing on alendronate. Serum CTX (carboxy-terminal collagen crosslinks) levels decreased further in the subjects who switched to denosumab than in those who continued with alendronate. In summary, denosumab suppresses bone resorption to a greater degree than the bisphosphonates, thereby leading to a greater increase in BMD.
Based on all of the available data, the FDA recently approved denosumab for the treatment of postmenopausal women who have a high risk of osteoporotic fractures, including those with a history of fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies. like bisphosphonates 20 , denosumab has also been used to reduce pain and other skeletal events in patients with metastatic cancer 35 . Of interest, a recent study by Thomas et al. 36 found that high, frequent doses of denosumab (120 mg per month) resulted in near complete or complete elimination of giant-cell tumours as evaluated by histology, suggesting that at least for this tumour type, denosumab may also have direct antitumour effects. Recently, denosumab gained approval from the FDA for the prevention of skeletal-related events in patients with bone metastases from solid tumours.
As noted above, the use of bisphosphonatesparticularly when administered in high doses in cancer patients -has been associated with the development of osteonecrosis of the jaw 23 . Similarly, several cases of osteonecrosis of the jaw have now also been reported with denosumab usage 37 . Perhaps one major concern about long-term denosumab use relates to its possible effects on the skin and immune system, as TRAIl (tumour necrosis factor-related apoptosis-inducing ligand) is suppressed by denosumab, and TRAIl is not just produced on osteoblasts but also on immune cells 26 .
In the large denosumab clinical trial, the active treatment group had statistically significant increases in the rates of eczema and hospitalizations for cellulitus, compared to placebo 31 . In addition, it has been shown that patients treated with denosumab have a slightly greater risk of recurrent neoplasms 38 , which, although not statistically significant, supports ongoing surveillance of such patients, particularly when used in the community setting in patients with co-morbidities that might have excluded them from participating in clinical trials.
Adherence to prescribed drugs and the cost of treatment are important considerations in the selection of treatment options and response to therapy. In a recent study, 77% of patients preferred denosumab injections every 6 months over weekly oral alendronate treatment 39 . The annual cost for the use of denosumab (two injections per year) is approximately US$1,650, which is very similar to the cost of the annual infusion of the bisphosphonate, zoledronic acid, but much higher than the cost of treatment with generic alendronate.
Strontium ranelate. Strontium ranelate (Protos; Servier) is a chemical compound that was originally developed as an anabolic agent for the treatment of postmenopausal osteoporosis. Strontium is taken up by bone, primarily through a physical mechanism, and is associated with limited calcium exchange in hydroxyapatite. Although its mechanism of action is not fully elucidated, it has both antiresorptive and anabolic properties. Strontium ranelate (2 g per day) was found to reduce vertebral fractures by 40% in a Phase III trial, and to reduce nonvertebral fractures by 16% in a second large randomized study. It is well tolerated with few adverse events 40, 41 , and is approved in Europe and Asia -but not in the United States -for the treatment of postmenopausal osteoporosis.
Teriparatide and PTH . A new class of anti-osteoporosis drugs was introduced in 2002, starting with the approval of teriparatide (a recombinant version of human PTH ) for the treatment of postmenopausal osteoporosis. PTH is a naturally occurring hormone secreted by the parathyroid glands in response to low circulating calcium levels. It acts directly on bone to stimulate resorption and preserve serum calcium, but it also indirectly influences calcium metabolism by acting on the kidney to enhance the activity of the 1α hydroxylase enzyme that converts 25-OH vitamin D to 1,25-dihydroxyvitamin D, thereby enhancing absorption of calcium and phosphate from the intestine. Thus, PTH has both direct and indirect influence on calcium metabolism (PTH acts directly on bone to mobilize calcium and indirectly through the kidney to promote calcium reabsorption and 1α hydroxylase activity, and through the gut to promote calcium absorption via 1,25-dihydroxyvitamin D) 42 . However, the mechanism of the anabolic action of PTH has been debated since the 1930s, when the first animal studies with PTH were completed. The ultimate paradox of PTH is that primary and secondary hyperparathyroidism with chronically high levels of PTH are associated with cortical bone loss and fractures, whereas intermittent PTH administration enhances trabecular bone mass and reduces fractures with modest effects on cortical bone. PTH targets lining cells and osteoblasts to generate a number of growth factors, including insulinlike growth factor 1 (IGF1) and RANKl 42 . RANKl is a critical modulator of osteoclastogenesis and is probably responsible for the coupling of resorption with 
β-catenin
An intracellular transcription factor activated by extracellular ligands such as the WnTs, as well as other intracellular signalling peptides.
formation during PTH therapy. Recent studies have shown that PTH also targets osteocytes and inhibits sclerostin, thereby further promoting bone formation through the WnT-β-catenin signalling pathway 43 .
In clinical studies, intermittent subcutaneous injections of PTH not only increased BMD but also reduced fractures of the spine and non-vertebral bones. In the largest randomized, placebo-controlled clinical trial using teriparatide in postmenopausal women with severe osteoporosis, 20 μg per day of PTH, administered subcutaneously, reduced spinal and non-vertebral fractures -but not hip fractures -by more than 50%, and substantially increased lumbar BMD by 8% a year 44 . Similar findings were noted in men with osteoporosis who were treated for 11 months. Unfortunately, the PTH trial in postmenopausal women was stopped after 20 months owing to concerns related to the development of osteosarcoma in rats treated with high doses of PTH . However, retrospective studies have found no association between osteosarcoma and primary or secondary hyperparathyroidism, and only two cases of osteosarcoma in PTH-treated patients have been reported in more than 9 years of market use 45 . More recently, recombinant human full-length PTH (PTH ) has shown similar benefits on the spine and hip and is approved in most European countries but not in the United States. The risk profile of PTH 1-84 is identical to teriparatide, but PTH 1-84 appears to have a slightly greater risk of hypercalcaemia 46 . Currently, it is recommended that PTH therapy should be limited to those individuals with moderate to severe osteoporosis, and only continued for 2 years. PTH is also approved for the treatment of glucocorticoid-induced osteoporosis. In general, PTH is well-tolerated, although nausea, flushing, hypotension and mild but asymptomatic hypercalcaemia (that is, serum calcium <11.0 mg per dl) can
Box 1 | Cathepsin K inhibitors
Cathepsin inhibitors form a new class of drugs for treating osteoporosis. Cathepsin K is the most abundantly expressed cysteine protease in osteoclasts, and it exhibits collagenolytic activity in bone tissues (mainly type 1 collagen) under acidic conditions; however, it is also expressed in skin and skin-derived cells. The most specific cathepsin K inhibitor developed so far is odanacatib.
In a Phase II trial 171 , the 50 mg dose of odanacatib was associated with a 5.5% increase in spine bone mineral density (BMD) and a 3.2% increase in total hip BMD after 24 months of treatment. This study has now been extended for an additional 12 months. Odanacatib was not associated with any increase in skin or upper respiratory tract infections during the treatment period, in contrast to earlier cathepsin K inhibitors. A Phase III fracture trial of odanacatib with 16,200 postmenopausal osteoporotic women is currently underway (ClinicalTrials.gov identifier: NCT00529373).
Of interest, the decreases in bone formation markers following odanacatib therapy were modest and transient compared with those seen with other antiresorptive therapies (M . McClung, personal communication) . These results were consistent with findings in bone biopsies that were available from a subset of the study participants 173 , which displayed a non-significant decrease in bone formation rate and mineralizing surface. In addition, levels of TRAP5b, a serum marker thought to reflect osteoclast numbers, did not change even with the highest dose of odanacatib. These data reflect a potentially important difference between odanacatib and other antiresorptive agents.
Odanacatib selectively inhibits the removal of matrix proteins, but it permits persistent osteoclast viability and cellular activity, including acid secretion. In general, cathepsin K inhibitors do not result in apoptosis of osteoclasts; therefore, osteoclasts are available to produce chemokines and growth factors such as the WNTs that are responsible for coupling with osteoblasts to maintain bone formation 120 . Also, the dramatic decrease in bone turnover with other antiresorptive treatments may carry long-term risks, including the accumulation of microcracks that cannot be repaired and microfractures that weaken the bone and increase the risk of fractures. Long-term clinical trials will be needed to demonstrate whether odanacatib will have a similar effect.
occur. Unlike the bisphosphonates, discontinuation of PTH can result in bone loss of 3 to 4% in the first year after PTH cessation 47 . This post-treatment effect is prevented by adding an antiresorptive drug after PTH is stopped. Despite the appeal of using an anabolic with an antiresorptive, there is no evidence so far to indicate that combinations of current classes of drugs have additive or synergistic effects 46, 47 , although this certainly does not preclude the possibility that more efficacious combinations of antiresorptive and anabolic agents may be discovered in the future. Finally, it should be noted that the marked increase in BMD with intermittent PTH use plateaus after 2 years of treatment. It is not clear whether there is resistance at the osteoblast level to continued administration of PTH or a reset of the remodelling balance based on the increase in bone resorption, but these factors are important to consider when developing new anabolic approaches for osteoporosis treatment. Cost and compliance with daily injections have been major limiting factors of PTH therapies for osteoporosis.
Newer formulations of PTH, including transdermal patches, have been studied in short-term dose-ranging Phase II trials. Also, oral agents (for example, calciolytics) that provoke intermittent PTH release by acting on the calcium sensing receptor in the parathyroids are under investigation as a means of capitalizing on the anabolic window produced by PTH. However, preliminary reports suggest that the administration of calciolytics does not fully recapitulate the pharmacokinetics of subcutaneously administered PTH. Another potential anabolic osteoporosis agent that is closely related to PTH is PTH-related protein (PTHRP), a peptide hormone that also activates the PTH receptor and regulates a number of homeostatic processes, including chondrocyte proliferation. Intermittent PTHRP administration has been shown to increase bone mass in postmenopausal women, and one pharmaceutical group has completed a Phase II study with daily subcutaneous administration of PTHRP for 12 months. BMD increased significantly in the spine and hip at both 6 and 12 months in this study (see below). These findings were comparable to results in women from the same study treated with teriparatide for 12 months.
Future anabolic therapies for osteoporosis
There is still a need for therapies that reduce fracture risk beyond the level achievable with bone-resorbing agents, particularly as virtually all of the currently available drugs do not eliminate the possibility of future fractures. Moreover, concern has grown about rare but important adverse effects of the bisphosphonates on skeletal sites such as the jaw (for example, osteonecrosis of the jaw) and the proximal femur (for example, subtrochanteric fractures). Drug discovery and development for osteoporosis is currently focused on several potential anabolic agents, with one major exception: cathepsin K inhibitors. One such inhibitor, odanacatib, is in Phase III trials
. The remainder of this article therefore focuses on advances in the understanding of osteoblast regulation and function that have revealed new opportunities for developing drugs to stimulate bone formation. These opportunities stem directly from ongoing bench and translational studies that have identified new pathways for regulating osteoblast differentiation and bone formation.
Targeting the WnT-β-catenin pathway The identification of patients with high bone mass owing to mutations in the WNT signalling pathway in 2002 led to an explosion of interest in modulating this pathway as a novel approach for treating for osteoporosis. WNTs are secreted glycoproteins that are crucial for the development and homeostatic renewal of many tissues, including bone tissue. FIGURe 2 depicts the central role that the canonical WNT pathway has in regulating osteoblast development 48, 49 . WNTs stimulate several signalling pathways by binding a receptor complex consisting of low-density lipoprotein receptor-related protein 5 (lRP5) and lRP6 and one of ten frizzled (FZ) molecules 50 . The canonical WNT signalling pathway, which involves stabilization of β-catenin and regulation of lymphoid enhancer-binding factor (lEF) and TCF transcription factors, has been the most extensively studied. The WNT pathway in osteoblasts is active in all osteoblast lineage cells, including pre-osteoblasts, lining cells and osteocytes 51 . Notably, WNT-β-catenin signalling may be a normal physiological response to mechanical loading 52 and is likely to participate in the fracture healing process 53 . WNT signalling has three major functions in osteoblast lineage cells: dictating osteoblast specification from osteo-and/or chondro-progenitors; stimulating osteoblast proliferation; and enhancing osteoblast and osteocyte survival. Within the BMU, WNTs also suppress bone resorption through suppression of osteoclast formation, partly by regulating RANKl levels in pre-osteoblasts 54 . WNT ligands are ubiquitous and can have significant pro-proliferative effects on both normal and neoplastic cells. Presumably owing to concerns about potential carcinogenicity, there has been no effort to develop experimental WNT-like ligands for stimulating bone formation. However, other aspects of the WNT-β-catenin pathway have been targeted, and selected examples are discussed below.
Sclerostin.
A target in the WNT pathway for which drug development efforts are the most advanced is sclerostin, a secreted WNT antagonist produced almost exclusively by osteocytes. Sclerostin regulates bone mass by binding to lRP5 and lRP6 to inhibit the canonical WNT-β-catenin signalling pathway [55] [56] [57] [58] [59] . The biological importance of sclerostin in humans is highlighted by two genetic diseases caused by loss of sclerostin function -sclerosteosis and van Buchem's disease -which are associated with markedly increased bone mass [60] [61] [62] [63] . As sclerostin is expressed almost exclusively in osteocytes, sclerostin inhibitors are anticipated to stimulate bone formation through WNT pathway activation and have reduced carcinogenic potential compared with broader WNT pathway activators. Moreover, in sclerostin-related genetic disorders, bone formation is high but bone resorption is reduced, suggesting that agents that suppress sclerostin might have dual properties in the remodelling unit.
Sclerostin-neutralizing monoclonal antibodies have been developed to inhibit the binding of sclerostin to the lRP5 receptor, resulting in the activation of the canonical WNT signalling pathway 64 . Initial studies in ovariectomized rats as a model of postmenopausal osteoporosis showed strong anabolic effects of the sclerostin antibody, with marked increases in bone formation on trabecular, periosteal, endocortical and intracortical surfaces following short-term treatment (5 weeks) 65 (FIG. 3) . A subsequent study in adolescent gonad-intact, non-human primates for 2 months using three different doses of the sclerostin-neutralizing monoclonal antibody demonstrated a significant increase in bone mineral content (BMC) and BMD at several skeletal sites (femoral neck, radial metaphysis and tibial metaphysis). Overall, there was an 11-29% increase in BMD from the baseline compared with vehicle-treated animals. There were also significant increases in trabecular thickness and bone strength at the lumbar vertebrae in the highest dose group 66 . A Phase I trial was conducted with 74 healthy men and postmenopausal women in a randomized, doubleblind, placebo-controlled ascending single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the sclerostin antibody 67 . The study demonstrated a dose-related increase in BMD of up to 5.3% at the lumbar spine and 2.8% at the total hip with a single subcutaneous dose of 10 mg per kg compared to placebo. Furthermore, the sclerostin-neutralizing antibody not only increased bone formation markers (procollagen type 1 amino-terminal propeptide (P1NP), bone-specific alkaline phosphatase (AlP) and osteocalcin (OCN)) but also decreased bone resorption (serum CTX) markers, resulting in a large anabolic window. Osteoblast and osteoclast activity was uncoupled following treatment with the sclerostin-neutralizing antibody; this uncoupling is also observed in sclerostosis or von Buchem's disease.
A Phase II dose escalation trial using dual-emission X-ray absorptiometry has recently been initiated with 419 postmenopausal women who have a T score between -2 and -3.5. In this study, different doses will be given once a month or once every 3 months. The primary end point is the percentage change in spine BMD from the baseline. This study will be particularly informative, as investigators will compare the efficacy of sclerostin antibody treatment with alendronate and teriparatide treatment. However, the long-term safety of a sclerostin monoclonal antibody, particularly with respect to the development of neoplasms, will await larger Phase III trials.
WnT-binding proteins. Other secreted WNT antagonists that could be blocked to stimulate the WNT signalling pathway and increase bone mass include secreted frizzled-related proteins (SFRPs) and WNT inhibitory factor 1 (WIF1), as both antagonists bind directly to WNT proteins and inhibit WNT signalling. Mesenchymal cells express endogenous WIF1, and its expression level decreases during osteoblast differentiation but increases during adipogenesis. Furthermore, overexpression of WIF1 in mesenchymal cells results in a significant decrease in AlP activity and an increase in adipogenesis. By contrast, complete knockdown of WIF1 leads to an increase in AlP activity in vitro 68 . Thus, either monoclonal antibodies or antisense RNA molecules against WIF1 or SFRPs would be expected to stimulate an increase in WNT activity and result in an anabolic bone response.
However, much like the WNTs, some consideration must be given to the possible oncogenic effects of pharmacological stimulation of the WNT pathway by inhibiting these antagonists. For example, Kansara et al. 69 showed that WIF1 indirectly suppressed β-catenin levels by binding to the WNTs and inhibited growth of mouse and human osteosarcoma cells. Deletion of WIF1 accelerated the development of radiation-induced osteosarcomas in vivo. In primary osteosarcomas, silencing of WIF1 by promoter hypermethylation was associated with loss of differentiation, increased β-catenin levels and increased cell proliferation. Compared with normal human osteoblasts, WIF1 mRNA and protein levels were significantly downregulated in several osteosarcoma cell lines. The downregulation of WIF1 mRNA expression was also associated with hypermethylation of its promoter in several cell lines 70 . Therefore, the development and use of WNT antagonists, as well as all agents that target the WNT-β-catenin pathway, must proceed with extreme caution owing to the potential for carcinogenicity. Further studies will be required to fully uncover the regulatory mechanisms involving WNTs and tumour development. DKK1 antagonists. DKK1 is another negative regulator of the WNT signalling pathway that acts similarly to sclerostin by directly binding to lRP5 and lRP6. Blocking the receptor leads to inhibition of osteoblastogenesis in various osteogenic cell lines and, in vivo, mice deficient in the Dkk1 gene develop extra digits 71 . The loss of a single Dkk1 allele resulted in an overall increase in bone mass 72 . Conversely, mice overexpressing DKK1 develop osteopaenia 73 . To date, most DKK1-inhibition studies have been carried out in association with different types of cancer cell lines or cancer mouse models. DKK1 is highly expressed in patients with multiple myeloma as well as in patients with breast cancer, and DKK1 contributes to the development and progression of myeloma and breast osteolytic bone metastases. A study by Bu et al. 74 demonstrated that although conditioned media from breast cancer cells blocked WNT3A-induced C2C12 osteoblast differentiation and OPG expression, conditioned media from cells in which DKK1 expression had been silenced was unable to do so. Serum from patients with multiple myeloma inhibited osteoblast differentiation in vitro, and this effect was blocked using a DKK1-neutralizing antibody. In vivo experiments on SCID-rab mice (mouse models with implanted rabbit bones) transplanted with myeloma cells with a DKK1-specific antibody stimulated bone formation and reduced bone loss and tumour growth 75 . In addition, an increase in BMD was observed in the control mice (which were not transplanted with the myeloma cells) treated with the DKK1 antibody. The DKK1-neutralizing antibody (BHQ880, which can neutralize both human and murine DKK1) prevented suppression of osteoblast numbers but did not prevent increases in osteoclast numbers. In addition, the DKK1-specific antibody prevented osteolytic bone disease, but it did not reduce overall tumour burden 76 . Thus, a possible alternative strategy to prevent oestrogen deficiency-induced osteoporosis could involve inhibiting the function of DKK1, as demonstrated by Wang et al. 77 . In this study, injection of sham or ovariectomized rats with end-capped phosphorothiate DKK1 antisense oligonucleotides resulted in an increase in bone volume and osteoblast numbers as well as a decrease in osteoclast numbers. In addition, DKK1 antisense oligonucleotide treatment decreased the expression of RANKl in the bone microenviroment. No studies using the DKK1 inhibitor in non-human primates or humans have been initiated so far. Moreover, unlike sclerostin, which is expressed primarily in bone, DKK1 is expressed in multiple tissues [78] [79] [80] . Thus, there are greater concerns regarding the use of DKK1 antagonists and risks of potential side effects, such as an increased incidence of tumours in, for example, the colon, where increased WNT signalling is associated with tumorigenesis [81] [82] [83] [84] .
Lithium. lithium has been used for decades to treat psychiatric disorders and is evidently not an emerging therapy for osteoporosis. However, owing to recent clinical and basic studies of the WNT-β-catenin pathway, lithium has been re-examined as an anabolic skeletal factor. Osteoporosis is prevalent in patients with bipolar disorders and other psychiatric conditions. The first choice of long-term treatment for these disorders has been lithium salts. However, lithium has a complex effect on calcium homeostasis and it is unclear whether lithium is protective or detrimental to the skeleton. For example, lithium can stimulate PTH release, and it has been clinically demonstrated that lithium therapy may be associated with a mild, reversible hyperparathyroid state [85] [86] [87] [88] [89] [90] . lithium was recently shown to activate the canonical WNT signalling pathway both in vitro and in vivo. lithium inhibits glycogen synthase kinase 3β (GSK3β), an enzyme that phosphorylates β-catenin in the cytoplasm, targeting it for ubiquitylation and degradation. Using lRP5 knockout and normal C57Bl/6 mice, Clement-lacroix et al. 91 demonstrated that lithium activated WNT signalling independently of the WNT receptor and resulted in significantly increased bone formation and bone mass in different lines of mice. However, administration of lithium carbonate caused bone loss in healthy, sexually mature Wistar rats 92 . Even though lithium treatment may lead to hyperparathyroidism, a recent study by Zamani et al. 93 found a significant decrease in bone formation and resorption markers and a significant increase in bone density in treated patients compared to control patients. Consistent with these findings, evaluation of data from large cohort studies demonstrated a decreasing relative risk of any fracture with an increasing accumulated dose of lithium 94, 95 . These findings were confirmed by Wilting et al. 96 , who also found a significantly increased risk of fractures after discontinuation of lithium treatment. Nevertheless, lithium has non-skeletal side effects that would undoubtedly limit its potential as an anabolic agent for osteoporosis.
Hormones, growth factors and cytokines One approach for treating osteoporosis is targeting extracellular molecules such as growth factors and cytokines. A number of extracellular factors have been identified as potential anabolic factors for skeletal metabolism, and some of them have been tested in clinical settings. In this section we summarize the recent findings of extracellular factors that are involved in skeletal metabolism and discuss their potential effectiveness for the treatment of osteoporosis.
IGF1, IGF2, IGFBPs and insulin.
Regulatory systems governed by IGFs and their binding proteins (IGFBPs) are operative in most tissues and exert profound effects on a wide range of metabolic processes [97] [98] [99] . Accumulating evidence in both human and animal studies demonstrates the anabolic role of IGF1 and IGF2 on the skeleton, partly through stimulating bone formation. For example, human IGF1 serum levels are robustly increased during puberty, when bone acquisition is maximized, but they decline with age and are later associated with bone loss. In genetically engineered animal models, the anabolic effect of circulating and skeletal IGF1 has been implicated in the physiological process of skeletal accrual, particularly for the cortical skeleton [100] [101] [102] [103] [104] [105] [106] [107] [108] . The effects of IGF1 on stromal cell differentiation appear to be bimodal, with IGF1 exhibiting mitogenic properties during early osteoblast development. However, IGF1 also promotes terminal osteoblast differentiation (for example, mineralization).
IGFBPs principally function as carriers for IGFs and regulate bone turnover by maintaining the proper IGF concentration in the skeletal microenvironment [109] [110] [111] . Molar excess of IGFBPs compared to IGFs reduces bone mass partly through inhibiting the access of IGFs to their receptor, whereas the lack of IGFBPs relative to IGFs leads to the osteoporotic phenotype by increasing the turnover of IGFs in the pericellular space. Indeed, administration of IGF2 in combination with IGFBP2 has anabolic effects on the skeleton 112, 113 . However, IGFBPs may have intrinsic biological activity independent of bound IGFs, and this may occur through their unique motifs, including their heparin-binding domain and RGD motif. For example, the heparin-binding domain of IGFBP2 has been implicated in the downregulation of phosphatase and tensin homologue (PTEN) expression, which may be beneficial for IGF1 signalling.
Given the anabolic properties of the IGF-IGFBP system, these peptides have been considered as potential therapeutic agents for the treatment for osteoporosis. In line with this, several small studies suggest that administration of recombinant human IGF1 (rhIGF1) could positively affect bone mass 114, 115 . Ghiron et al. 115 evaluated the bone formation and resorption markers in 16 healthy elderly women (71.9 ± 1.3 years of age) who were administered with a high dose of rhIGF1 (60 μg per kg per day) or a low dose of rhIGF1 (30 μg per kg per day) for 28 days. Bone formation markers, including OCN, skeletal AlP and type 1 procollagen carboxy-terminal extension peptide (C1CP) were increased by rhIGF1 treatment, whereas bone resorption markers such as urine hydroxyproline (OHP), total pyridinolines (PyDs) and N-telopeptide showed dose-dependent differences. High-dose rhIGF1 increased expression of these resorption markers, but low-dose rhIGF1 did not appreciably affect bone resorption. These data suggest that low-dose rhIGF1 may be considered as an anabolic treatment, as it increases bone formation with only minimal increases in bone resorption.
rhIGF1 has also been studied in patients with anorexia nervosa, which is characterized by amenorrhoea, low BMD, reduced body weight, low serum IGF1 levels and growth hormone resistance. Grinspoon et al. 114 reported that rhIGF1 caused an increase in BMD in these patients and, when combined with oral contraceptive pills, rhIGF1 showed a greater increase in BMD than oral contraceptives alone. As rhIGF1 has a very short half-life, combination therapy with its carrier (such as rhIGFBP3) has been proposed 116 . Boonen et al. 116 evaluated the effect of rhIGF1-rhIGFBP3 combination therapy on the recovery of bone mass in patients with recent hip fracture after surgery (aged 65-90 years). Interestingly, bone loss in the contralateral hip was recovered in patients with combinational therapy, but placebo-treated patients failed to regain lost bone. However, IGF1 also stimulates bone resorption, and so it seems unlikely that therapy with this peptide could be continued indefinitely. In addition, metabolic adverse effects such as hypoglycaemia and hypophosphataemia caused by the activation of the IGF receptor in other tissues may limit the widespread application of this therapy.
Insulin has been used as a form of treatment for type 1 and type 2 diabetes mellitus for almost 90 years. However, two recent studies suggest that insulin has novel activity on the skeletal remodelling unit that cannot be duplicated by IGF1. The Clemens laboratory demonstrated that absence of the insulin receptor in osteoblasts leads to markedly decreased bone formation and an obesity phenotype 117 . The Karsenty laboratory showed that insulin mediates bone remodelling by suppressing TWIST2 (a basic helix-loop-helix protein) and OPG, thereby leading to higher bone turnover 118 . Moreover, as noted below, OCN, a bone-specific protein, enhances insulin sensitivity and secretion, which in turn could lead to increased bone formation. Further studies are required to determine whether insulinotropic agents might be useful in the treatment of osteoporosis.
TGFβ. TGFβ has complex effects on bone tissue, but there has been considerable interest in this growth factor, as demonstrated recently by Tang et al. 119 , who showed that active TGFβ1 released during bone resorption coordinates bone formation by inducing the migration of osteoblast precursors. This has led to the proposal that TGFβ1 is a factor that couples bone resorption to bone formation signalling. Additional factors produced by osteoclasts that appear to serve a similar coupling function include sphingosine kinase 1, WNT10B and bone morphogenetic protein 6 (ReF. 120) .
Collectively, these findings raise the possibility that regulating the production of TGFβ or other coupling factors in the bone microenvironment may represent a novel approach for increasing osteoblast numbers and/ or activity. However, like other growth factors, TGFβ is ubiquitously expressed; therefore, using this peptide as a treatment modality might have adverse nonskeletal effects.
OCn. OCN is an osteoblast-specific secretory protein that is the major non-collagenous protein in the extracellular matrix of bone 121 . OCN undergoes γ-carboxylation, which occurs post-translationally on glutamic acid residues, converting them to γ-carboxyglutamic acid (Gla) residues. This process increases the affinity of OCN for the extracellular matrices, especially hydroxyapatite 122, 123 . OCN has been widely used as a marker for bone turnover and bone formation 124 ; however, the exact role of OCN still remains unknown 125 . For example, OCN null mice are obese and insulin-resistant, suggesting that bone has an integral role in energy metabolism, partly through OCN 126, 127 . Un-carboxylated and under-carboxylated forms of OCN can circulate and function as endocrine factors increasing the production of insulin in the β-cells of the pancreas and adiponectin in adipocytes 121, 126, 127 , thus exerting a systemic glucose-lowering effect. Interestingly, OCN bioactivity is regulated negatively by adipocytes through increased sympathetic nervous tone driven by leptin 121, 127, 128 , resulting in decreased insulin secretion from β-cells.
Recently, two independent laboratories have expanded our understanding of the metabolic and skeletal functions of OCN. Conditional deletion of the insulin receptor in osteoblasts leads to impaired bone formation and insulin resistance 117 . This occurs through modulation of the ratio of under-carboxylated OCN relative to total OCN. Under-carboxylated OCN is presumed to be the active metabolic form and its release from the skeletal matrix is triggered by bone resorption through insulin signalling and suppression of OPG 118 . Thus, modulating OCN activity could improve insulin sensitivity, which might also prove beneficial for skeletal health. However, whether this pathway is operative in humans has yet to be determined. Clinical studies have demonstrated that serum OCN and under-carboxylated OCN levels are inversely associated with glucose levels [129] [130] [131] [132] [133] [134] . However, glucose metabolism in patients treated with warfarin, which blocks γ-carboxylation of several molecules including OCN, has not been studied systematically. In addition, a receptor for OCN has not yet been identified. Clearly, further clinical and translational studies are needed to clarify the effectiveness of OCN in the regulation of bone and glucose metabolism in humans. However, the possibility that one could administer an agent that enhances glucose sensitivity and is either neutral or anabolic for bones is certainly tantalizing.
Antagonists of PPARγ
Peroxisome proliferator-activated receptor-γ (PPARγ) is a member of the PPAR family of transcriptional factors and nuclear receptors and has a critical role in many aspects of cellular activities, including cell differentiation, lipid and glucose metabolism, and neoplasm development [135] [136] [137] . Alternative splicing generates various PPARγ isoforms including PPARγ1 and PPARγ2, the two most common isoforms of PPARγ. PPARγ1 is expressed in most tissues, but expression of PPARγ2 is limited to adipogenic cells. PPARγ2 has been identified as a critical transcription factor regulating adipogenesis and adipocyte metabolic functions.
Thiazolidinediones (TZDs) are ligands for PPARγ and have been used frequently for the treatment of type 2 diabetes mellitus because of their lipid and glucose-lowering effects [138] [139] [140] [141] [142] . Recent data from clinical and animal studies point to adverse effects of these agents on skeletal metabolism, which may result in bone loss and fractures [143] [144] [145] . By contrast, PPARγ heterozygous mice have high bone mass and reduced marrow adiposity 146 . Similarly, inhibition of a downstream target of PPARγ, nocturnin, results in enhanced osteogenesis and suppressed adipogenesis 147 . This occurs because PPARγ is a master regulator of mesenchymal cell fate, favouring the adipogenic lineage and suppressing osteoblastogenesis when activated. In addition to changing marrow stromal cell allocation, activation of PPARγ increases osteoblast and osteocyte apoptosis, possibly through reduction of IGF1, and enhances osteoclastogenesis by stimulating FOS expression in osteoclast precursors. Thus, inhibition of PPARγ activity could be a pharmacological means of treating osteoporosis. This concept has been studied in experimental models. Krause et al. 148 reported that the PPARγ inhibitor, GW9662, enhanced osteogenic markers in human mesenchymal stem cells.
However, treatment with another PPARγ antagonist -bisphenol-A-diglycidyl ether (BADGE) -did not prevent bone loss in streptozoticin-induced type 1 diabetic mice, although BADGE inhibited the development of marrow adiposity in these mice 149 . As PPARγ could be a positive regulator for osteoclastogenesis, it is possible that PPARγ antagonists increase skeletal mass partly through inhibiting bone resorption, although this hypothesis has not been verified 150, 151 . These lines of evidence demonstrate that targeting PPARγ activity could be a promising strategy for the treatment of osteoporosis. Indeed, several companies are exploring this target, although further animal, clinical and translational studies will be required (FIG. 4) .
Serotonin
Serotonin (5-hydroxytrophan) is a neurotransmitter that affects appetite, energy balance and behavioural and emotional activity, and also functions to modulate gastrointestinal peristalsis, platelet contraction and haemostasis, depending on its site of synthesis [152] [153] [154] [155] . Serotonin synthesis is catalysed by the rate-limiting tryptophan hydroxylase (TPH) enzymes 156 . Circulating serotonin, which accounts for 95% of the total serotonin in the body, is generated in the enterochromaffin cells of the duodenum by TPH1 (ReF. 157) . Circulating serotonin is taken up principally by platelets through the serotonin transporter (5-HTT) and it does not cross the bloodbrain barrier. By contrast, serotonin in the brain is mainly produced in the brain stem by TPH2 (ReF. 158) .
Circulating and central nervous system (CNS) serotonin may have opposing effects on skeletal metabolism. yadav et al. 159 reported that suppression of circulating serotonin by inhibiting TPH1 expression in the gut resulted in a high bone mass phenotype, suggesting that circulating serotonin functions as a hormone that suppresses bone acquisition. By contrast, suppression of brainderived serotonin by targeting the TPH2 gene decreased bone mass through the activation of the hypothalamus and stimulation of the sympathetic nervous system 160 . This indicates that brain serotonin is a neurotransmitter regulating bone mass in a positive way.
Given the effects of serotonin as a modulator of behavioural and emotional activity, a number of serotonin-targeted drugs have been developed to treat psychiatric disorders. Two classes of drugs, secondgeneration antipsychotic agents (SGAs) and selective serotonin reuptake inhibitors (SSRIs), have been widely prescribed to treat psychosis. Unexpectedly, however, these agents have been shown to have a deleterious effect on skeletal mass 95, [161] [162] [163] [164] [165] [166] [167] [168] . SGAs such as risperidone (Risperdal; Johnson & Johnson), which have antagonist activity at the 5-HT 2A receptor, and to a lesser extent the dopamine D 2 receptor 169 , have been implicated in bone loss and associated with a higher fracture risk 161, 162, 168 . Hyperprolactinaemia caused by the inhibition of dopamine D 2 receptor signalling could partially account for the bone loss caused by SGAs, because hyperprolactinaemia can stimulate bone resorption by suppressing gonadotropin secretion 170 . However, it is still possible that SGAs cause bone loss by inhibiting serotonin receptor signalling. Indeed, male mice treated with risperidone exhibit profound bone loss with no effect on their serum prolactin levels (C.J.R., unpublished observations).
SSRIs, which inhibit serotonin uptake by 5-HTT to increase the local concentration of serotonin, have also been implicated in reduced bone mass and fractures [163] [164] [165] [166] [167] . Because SSRIs could increase pericellular serotonin concentrations both in the CNS and the skeletal microenvironment, the exact mechanisms by which SSRIs reduce bone mass are still unclear. Nevertheless, these lines of evidence clearly suggest that serotonin signalling is involved in skeletal metabolism and manipulating this pathway is a potential target for the treatment for osteoporosis. In fact, a small molecule that inhibits TPH1 (lP533401) was shown to possess an anabolic effect on the skeleton of mice in one preliminary study 171 . Further translational and preclinical studies will be required to shed light on this novel approach for osteoporosis treatment.
Outlook and challenges for anabolic agents Drug discovery and development for osteoporosis is now largely focused on anabolic agents (with the notable exception of the cathepsin K inhibitors discussed in BOX 1) , and several of the approaches discussed above could lead to marketed therapies in the next decade. PTHRP (BOX 2) and a sclerostin-neutralizing monoclonal antibody show particular potential for moving into Phase III trials. However, the road to approval of new osteoporosis therapies has several important obstacles.
First, the only end point recognized by European and American regulatory agencies for establishing the efficacy of new osteoporosis drugs is a reduction in fractures over a minimum of 3 years. low BMD is a risk factor for fracture, but an increase in density is not sufficient to gain regulatory approval. Indeed, several agents have been shown to increase BMD, but they do not reduce the number of fractures. After completing the requisite animal studies (two models are required) and the toxicology work, sponsors must have doseranging Phase II studies ready before embarking on very large and expensive Phase III fracture trials. With the exception of PTHRP, which could potentially be studied in a non-inferiority fracture trial owing to its resemblance in structure and function to PTH 1-34 , any of the other agents mentioned above would currently have to be tested through randomized placebocontrolled trials. Even assuming that sufficient efficacy is achieved, demonstrating acceptable safety will be a major challenge, particularly for newer agents that may affect non-skeletal tissues (for example, agents affecting WNT-β-catenin signalling and neoplastic growth). Not only does the design of the trial have to include assurances that there is adequate power to assess fracture-risk reduction, but adjudication of events from other possible non-skeletal effects needs to be a major component of the research design.
Second, there are now several drugs for treating osteoporosis. This has led some individuals to propose a halt to randomized placebo-controlled trials for new osteoporosis agents. A discussion of those issues is beyond the scope of this paper, but is highlighted in a recent perspective article in the New England Journal of Medicine 172 . Suffice it to say, recruitment into a Phase III randomized placebo-controlled trial for a new osteoporosis drug will be difficult and will require larger numbers of subjects, particularly if women at highest risk are excluded from participating. Improving recruitment and retention of subjects will require more careful consideration of individual risk profiles and may include a more personalized approach, such as a FRAX analysis (a tool designed by the World Health Organization to assess and determine a patient's 10-year fracture risk) at the time of informed consent.
Third, even if approval is gained, there is a major push at the regulatory level for more in-depth post-marketing trials that are more than just observational analyses. These would include multiyear extensions, either open label or blinded, in a Phase III trial design and further scrutiny of adverse event reporting. Nonetheless, there are major opportunities for new drug development in osteoporosis treatment. The number of targets has increased substantially, and as our knowledge of bone biology expands, this list is sure to grow. Hence, cautious optimism pervades the world of osteoporosis medicine with respect to newer therapeutic opportunities for skeletal restoration.
Box 2 | Parathyroid hormone-related protein
Parathyroid hormone-related protein (PTHRP) is a naturally occurring polypeptide that is closely related to PTH and activates the same receptor as PTH (PTHR1) 174 . It is expressed in many tissues, but is found in high levels at the growth plate, in osteoblasts and within mammary tissues. It was cloned from cancer cells and identified as the circulating cause of hypercalcaemia of malignancy. Originally thought to be a potent stimulus of bone resorption and hence hypercalcaemia, experimental studies using intermittent PTHRP have shown that it has significantly similar anabolic properties to PTH . PTHRP was first shown to be effective in treating low bone mass in laboratory animals, but was later studied for safety and efficacy in humans as well 175 .
One study of PTHRP was performed to determine whether it could increase bone mass in postmenopausal women with osteoporosis when administered daily by subcutaneous injection for 3 months 170 . This double-blind, placebo-controlled, randomized clinical study enrolled 16 postmenopausal women with osteoporosis between 50 and 75 years of age 176 . All patients had been on hormone replacement therapy for an average of 8 years and still had osteoporosis. Women who had been taking any other type of osteoporosis medication were excluded from the study. Half of the subjects self-administered PTHRP (400 μg per day) and the other half injected a placebo. The patients were followed up for 3 months and the participants tolerated treatment without developing hypercalcaemia, hypotension, nausea, flushing or other adverse effects. The lumbar spine BMD increased by 4.7% during the 3-month treatment period, and this was a larger increase in bone mass than observed with either antiresorptives or PTH . Subsequently, a 3-week dose-ranging study to determine the maximum tolerable dose was performed. Hypercalcaemia developed only at the highest dose (750 μg per day) and in one of six individuals 175 . Bone formation markers increased to 40% with the higher doses, and resorption indices at day 21 were only modestly increased for the patients on doses of 625 μg per day and 750 μg per day.
A similar but longer Phase II dose ranging study was performed by Radius Pharmaceuticals with PTHRP 1-34 (BA058) versus PTH in more than 200 postmenopausal women. The results remain unpublished but at a meeting on anabolic treatments for osteoporosis, Radius reported increases in spine and hip BMD that equalled or exceeded teriparatide (specifically with PTH . (L. O'Dea, personal communication). Thus, PTHRP remains a potentially important future anabolic treatment for osteoporosis, particularly if this agent increases bone formation more than bone resorption. However, the long-term safety and fracture efficacy will only be determined by a large Phase III clinical trial.
